Return on Equity (ROE)
since 2005
Calculation
Eli Lilly & Co., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net income (loss)1 | ÷ | Total Eli Lilly and Company shareholders’ equity1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 74.62% | = | 100 | × | 10,590,000) | ÷ | 14,192,100) |
| Dec 31, 2023 | 48.65% | = | 100 | × | 5,240,400) | ÷ | 10,771,900) |
| Dec 31, 2022 | 58.64% | = | 100 | × | 6,244,800) | ÷ | 10,649,800) |
| Dec 31, 2021 | 62.16% | = | 100 | × | 5,581,700) | ÷ | 8,979,200) |
| Dec 31, 2020 | 109.79% | = | 100 | × | 6,193,700) | ÷ | 5,641,600) |
| Dec 31, 2019 | 319.09% | = | 100 | × | 8,318,400) | ÷ | 2,606,900) |
| Dec 31, 2018 | 32.88% | = | 100 | × | 3,232,000) | ÷ | 9,828,700) |
| Dec 31, 2017 | -1.76% | = | 100 | × | (204,100) | ÷ | 11,592,200) |
| Dec 31, 2016 | 19.54% | = | 100 | × | 2,737,600) | ÷ | 14,007,700) |
| Dec 31, 2015 | 16.53% | = | 100 | × | 2,408,400) | ÷ | 14,571,300) |
| Dec 31, 2014 | 15.55% | = | 100 | × | 2,390,500) | ÷ | 15,373,200) |
| Dec 31, 2013 | 26.57% | = | 100 | × | 4,684,800) | ÷ | 17,631,400) |
| Dec 31, 2012 | 27.69% | = | 100 | × | 4,088,600) | ÷ | 14,765,200) |
| Dec 31, 2011 | 32.11% | = | 100 | × | 4,347,700) | ÷ | 13,541,700) |
| Dec 31, 2010 | 40.82% | = | 100 | × | 5,069,500) | ÷ | 12,420,300) |
| Dec 31, 2009 | 45.45% | = | 100 | × | 4,328,800) | ÷ | 9,523,700) |
| Dec 31, 2008 | -30.76% | = | 100 | × | (2,071,900) | ÷ | 6,735,300) |
| Dec 31, 2007 | 21.61% | = | 100 | × | 2,953,000) | ÷ | 13,664,400) |
| Dec 31, 2006 | 24.25% | = | 100 | × | 2,662,700) | ÷ | 10,980,700) |
| Dec 31, 2005 | 18.34% | = | 100 | × | 1,979,600) | ÷ | 10,791,900) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
Comparison to Competitors
Eli Lilly & Co., ROE, long-term trends, comparison to competitors
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 74.62% | 128.66% | 69.59% | — | — | — | 19.68% | — | — | 15.03% | — | — |
| Dec 31, 2023 | 48.65% | 46.94% | 107.78% | 27.27% | 8.91% | 24.81% | 51.11% | 0.97% | 2.38% | 15.22% | 12.83% | 20.59% |
| Dec 31, 2022 | 58.64% | 68.60% | 178.97% | 20.37% | 14.39% | 21.62% | 23.36% | 31.57% | 32.79% | 19.14% | 15.80% | 23.88% |
| Dec 31, 2021 | 62.16% | 74.91% | 87.96% | 19.46% | 14.24% | 29.55% | 28.20% | 34.17% | 28.47% | 43.03% | 18.94% | 23.19% |
| Dec 31, 2020 | 109.79% | 35.30% | 77.20% | -23.84% | 9.17% | 0.68% | 23.25% | 27.91% | 15.21% | 31.86% | 18.47% | 31.22% |
| Dec 31, 2019 | 319.09% | — | 81.07% | 6.66% | 9.94% | 23.91% | 25.42% | 37.99% | 25.77% | 19.08% | 12.45% | 19.34% |
| Dec 31, 2018 | 32.88% | — | 67.15% | 35.07% | 9.40% | 25.51% | 25.60% | 23.30% | 17.59% | 27.91% | 10.65% | 47.28% |
| Dec 31, 2017 | -1.76% | 104.16% | 7.84% | 8.58% | 9.45% | 22.64% | 2.16% | 6.97% | 29.47% | 19.51% | 8.76% | 12.99% |
| Dec 31, 2016 | 19.54% | 128.41% | 25.85% | 27.55% | 11.10% | 71.48% | 23.49% | 9.78% | 12.12% | 20.13% | 9.39% | -9.69% |
| Dec 31, 2015 | 16.53% | 130.39% | 24.71% | 10.97% | 14.17% | 97.70% | 21.66% | 9.94% | 10.75% | 17.40% | 9.25% | -59.19% |
| Dec 31, 2014 | 15.55% | 101.84% | 20.01% | 13.49% | 11.11% | 78.45% | 23.40% | 24.50% | 12.81% | 13.69% | 9.22% | -68.70% |
| Dec 31, 2013 | 26.57% | 91.90% | 23.00% | 16.91% | 12.04% | 27.05% | 18.68% | 8.85% | 28.83% | 21.74% | 7.55% | -32.81% |
| Dec 31, 2012 | 27.69% | 156.85% | 22.80% | 14.39% | 12.58% | 27.84% | 16.74% | 11.63% | 17.93% | 60.24% | 7.62% | -10.71% |
| Dec 31, 2011 | 32.11% | — | 19.35% | 23.25% | 12.85% | 41.60% | 16.94% | 11.50% | 12.18% | -45.65% | 8.84% | 3.76% |
| Dec 31, 2010 | 40.82% | — | 19.32% | 19.74% | 13.08% | 49.48% | 23.57% | 1.58% | 9.40% | -19.79% | 6.74% | -149.74% |
| Dec 31, 2009 | 45.45% | — | 20.32% | 71.49% | 9.90% | 41.40% | 24.25% | 21.85% | 9.59% | -17.10% | 5.51% | -58.57% |
| Dec 31, 2008 | -30.76% | — | 20.58% | 42.86% | 13.43% | 48.43% | 30.46% | 41.63% | 14.08% | -19.75% | 6.66% | -192.51% |
| Dec 31, 2007 | 21.61% | — | 17.72% | 20.50% | 15.08% | 46.69% | 24.41% | 18.01% | 12.53% | -22.94% | 5.25% | -144.23% |
| Dec 31, 2006 | 24.25% | — | 15.56% | 15.86% | 16.89% | -65.54% | 28.11% | 25.25% | 27.10% | -47.24% | 1.21% | -40.89% |
| Dec 31, 2005 | 18.34% | — | 17.96% | 26.77% | 17.67% | 26.88% | 27.49% | 25.85% | 12.32% | -83.72% | 7.99% | -85.05% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Eli Lilly & Co., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Eli Lilly & Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 74.62% | — |
| Dec 31, 2023 | 48.65% | 20.65% |
| Dec 31, 2022 | 58.64% | 27.99% |
| Dec 31, 2021 | 62.16% | 29.75% |
| Dec 31, 2020 | 109.79% | 17.22% |
| Dec 31, 2019 | 319.09% | 27.68% |
| Dec 31, 2018 | 32.88% | 26.29% |
| Dec 31, 2017 | -1.76% | 14.59% |
| Dec 31, 2016 | 19.54% | 22.19% |
| Dec 31, 2015 | 16.53% | 21.44% |
| Dec 31, 2014 | 15.55% | 20.91% |
| Dec 31, 2013 | 26.57% | 20.33% |
| Dec 31, 2012 | 27.69% | 18.27% |
| Dec 31, 2011 | 32.11% | 15.52% |
| Dec 31, 2010 | 40.82% | 13.99% |
| Dec 31, 2009 | 45.45% | 20.34% |
| Dec 31, 2008 | -30.76% | 21.31% |
| Dec 31, 2007 | 21.61% | 17.07% |
| Dec 31, 2006 | 24.25% | 21.86% |
| Dec 31, 2005 | 18.34% | 19.08% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Eli Lilly & Co., ROE, long-term trends, comparison to industry (health care)
| Eli Lilly & Co. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 74.62% | — |
| Dec 31, 2023 | 48.65% | 18.07% |
| Dec 31, 2022 | 58.64% | 22.47% |
| Dec 31, 2021 | 62.16% | 22.98% |
| Dec 31, 2020 | 109.79% | 16.02% |
| Dec 31, 2019 | 319.09% | 20.98% |
| Dec 31, 2018 | 32.88% | 17.71% |
| Dec 31, 2017 | -1.76% | 14.11% |
| Dec 31, 2016 | 19.54% | 18.09% |
| Dec 31, 2015 | 16.53% | 18.16% |
| Dec 31, 2014 | 15.55% | 18.60% |
| Dec 31, 2013 | 26.57% | 18.15% |
| Dec 31, 2012 | 27.69% | 17.49% |
| Dec 31, 2011 | 32.11% | 15.29% |
| Dec 31, 2010 | 40.82% | 14.41% |
| Dec 31, 2009 | 45.45% | 19.34% |
| Dec 31, 2008 | -30.76% | 18.87% |
| Dec 31, 2007 | 21.61% | 16.99% |
| Dec 31, 2006 | 24.25% | 20.34% |
| Dec 31, 2005 | 18.34% | 18.42% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).